Instadose Pharma Corp.
Instadose Pharma Corp. (INSD) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001697587 · INSD · OTC · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001697587 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Instadose Pharma Corp. (OTC: INSD) has submitted 58 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001697587, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Instadose Pharma Corp.'s most comprehensive regulatory disclosure. The most recent Instadose Pharma Corp. 10-K was filed on 2022-03-15 for fiscal year ending 2022. Historical INSD 10-K annual reports are available from 2017 through 2022.
Investors researching Instadose Pharma Corp. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
INSD SEC Filings · 8 questionsInstadose Pharma Corp. (INSD) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 58 filings and access original documents at no cost. Instadose Pharma Corp.'s CIK is 0001697587.